Gatfatite ACME drugs reduce total cholesterol (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Atorvastatin

Ingredient

Composition information	Content
Atorvastatin	10mg

Uses

indications

Gatfatite drug indicated in the following cases:

Atorvastatin is designated to support diets to reduce total cholesterol, LDL-Cholesterol, Apolipoprotein B and Triglycerides in patients with primary hyperlipidemia, mixed blood lipids and hyperlested blood cholesterol with heterozygall.

Atorvastatin is also appointed to reduce total cholesterol and reduce LDL-C in patients with homozygous family lipid hyperlemen as a drug that supports other treatments (for example: LDL-APHERESIS, Cholestyramine) or when other treatments cannot be implemented.

Preventive cardiovascular complications in older patients: Reducing the risk of myocardial infarction in adults with high blood pressure without clinical coronary artery disease, but at least 3 risks of coronary artery disease such as age, men, smoking, type 2 diabetes, left ventricular hypertrophy, specific abnormalities on electrocardiograms, urinary protein, cholesterol ratio in plasma is high in cholesterol with high weight in cholesterol with high weight (HDL-C)> 6, or a family with a history of coronary artery disease before adulthood.

Pharmacokology

Atorvastatin is a selective inhibitor and competition for reducing enzyme HMG-CoA, inhibiting the conversion of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-COA) into Mevababonate, a precursor of sterols, including cholesterol cholesterol.

Cholesterol and triglycerides circulate in the blood as lipoprotein molecules. These molecules are divided into high molecular weight lipoprotein (HDL), medium molecular weight lipoprotein (IDL), low molecular weight lipoprotein (LDL) and Lipoprotein very low molecular weight (VLDL).

triglycerides and cholesterol combined into VLDL in the liver. From the liver they are released into plasma to go to peripherals. LDL is formed from VLDL and is degenerated mainly through LDL receptors. Clinical and pathological studies have shown that increasing total cholesterol levels, LDL cholesterol and Apolipoprotein B (APO B) in the blood increases atherosclerosis in humans and increases the risk factors for cardiovascular disease, while increasing HDL cholesterol reduces the risk of cardiovascular disease.

Atorvastatin reduces total cholesterol, LDL cholesterol and apoprotein B in patients with hypercholesterol blood cholesterol and heterozygous, hyperplasia and mixed blood lipids. It also reduces VLDL cholesterol and triglycerides and increases HDL cholesterol and Apolipoprotein A-1.

Atorvastatin reduces total cholesterol, LDL cholesterol, VLDL cholesterol, APO B, Triglycerides, and non -HDL cholesterol and HDL cholesterol hyperplasia in patients with hyperemical hyperemper. It reduces the average density cholesterol (IDL cholesterol) in patients with blood lipoprotein metabolism disorders. Reducing total cholesterol, LDL-Cholesterol, Apolipoprotein B has been shown to reduce the risk of cardiovascular and cardiovascular death.

Pharmacokinetics

absorption

Atorvastatin absorbs rapidly after drinking, the maximum concentration in plasma is achieved after 1 to 2 hours. Atorvastatin absorption level increases corresponding to the dose. Birth of Atorvastatin (parent substance) is about 14% and the whole bioavailability of the substance has a HMG-coa-eliminating enzyme inhibitors about 30%.

Distribution

The distribution of Atorvastatin is about 381 liters. More than 98% Atorvastatin is attached to plasma proteins. Based on mice observations, Atorvastatin may eliminate milk.

Metabolism

Atorvastatin metabolizes mainly into hydroxylation derivatives at Ortho and Para positions and oxidized products at Beta.

Elimination

Atorvastatin and its metabolites are excreted mainly into bile after the metabolism through the liver and/or outside the liver. However, the drug does not go through the intestinal cycle. Atorvastatin's sale time in humans is about 14 hours, but the sale time of HMG-CAA reducing enzyme inhibits about 20 to 30 hours due to the main metabolites of Atorvastatin.

Special subjects

kidney failure

The pathology in the kidney does not affect the concentration of plasma and the treatment effect of Atorvastatin and its active metabolites.

Hepatic failure

Atorvastatin and its active metabolites increased significantly in patients with alcoholic liver failure (Child- Pugh B) (CMAX increased by 16 times, AUC increased by about 11 times). Elderly

Atorvastatin concentration and active metabolites in older plasma in elderly patients are higher than young patients with the same level of lipid in plasma.

Children

According to studies, the disposal time of Atorvastatin when using oral children is proportional to adults at the body weight ratio.

Gender

There is no significant difference between pharmacokinetics and effectiveness of drugs in men and women.

polymorphism SL0cib1

Metabolism of HMG-CAA reducing enzymes inhibitors, including Atorvastatin related to OATPTB1. In patients with polymorphism SLCO1B1, there is an increased risk of Atorvastatin levels leading to an increase in the risk of muscle pattern - a serious side effect of the drug.

Before taking Gatfatite ACME drugs reduce total cholesterol (3 blisters x 10 tablets)

How to use

Before Atorvastatin treatment, try to control high blood cholesterol with an appropriate diet, exercise and lose weight in obese patients, and treat health problems. Patients should continue to follow a standard diet that lowers cholesterol while treatment with Atorvastatin.

Dosage

Select the dose suitable for LDL-C increase, treatment and response objectives of patients.

Atorvastatin is taken regardless of the meal.

Normal starting dose: 10mg/time/day. After starting and/or adjusting the dose of Atorvastatin, the lipid level should be tested for 2-4 weeks and adjust the dose accordingly. The maximum dose is 80mg/time/day.

Patients with renal failure: Unnecessary dose adjustment.

Patients with liver failure: should be used body

Elderly patients: It is not necessary to adjust the dose

Children: For children 10 years of age and older, Atorvastatin's recommended starting dose is 10mg/day, up to 20mg/time/day. Need to regularly monitor the ability to tolerate drugs and other reactions of children. With children under 10 years old, experience is limited.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What do

do when overdose? If overdose, patients need to monitor liver function, concentration of CK in the blood and take supportive treatments.

Hemorrhage is not significant in this case due to Atorvastatin strongly attached to plasma proteins.

In an emergency, call the 115 emergency center immediately or go to the nearest local health station.

What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Side Effects

Unwanted effects (ADR) when using gatfatite that you may encounter:

Infections and parasites:

Common: Nasomitis.

Rare: platelets.

immune system disorders:

Rare: Allergic reactions.

Very rare: Anaphylaxis.

Common: Hyperglycemia.

Less: nightmares, insomnia.

Nervous system disorders:

Common: headache.

Less: blurred vision.

Rare: visual disorders

Less: tinnitus.

Very rare: hearing loss.

Common: sore throat, nosebleeds.

Gastrointestinal disorders

Common: constipation, flatulence, indigestion, nausea, diarrhea.

Uncommon: Hepatitis.

Less: urticaria, rash, itching, hair loss.

Common: muscle pain, joint pain, pain in the limb, muscle spasm, joint swelling

Very rare: Big breasts in men.

Less: fatigue, weakness, chest pain, peripheral edema, fatigue, fever.

Testing:

Common: Unusual liver function test, CK increases.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

anti -contraindicated gatfatite in the following cases:

Hypersensitivity to any ingredients of the drug.

Be cautious when using

Before using Atorvastatin, try to control hyperchemical blood cholesterol by diet, exercise, weight loss in obese patients.

affect the liver

It is necessary to conduct liver function tests before starting treatment and periodically later in patients (about 4 weeks).

Patients with alat or Asat increases should be monitored until these indicators return to normal, if the concentration of these enzymes increases above 3 times limited to normal (GHT) and prolonged, need to reduce the dose or stop taking the drug.

Be cautious when taking medicine for patients to drink a lot of alcohol or a history of liver disease.

Prevention of stroke

Be cautious when using Atorvastatin to prevent stroke in patients without coronary heart disease (CHD), a recent stroke or transient anemia (ray).

The effect of skeletal muscles

Atorvastatin can cause muscle pain, muscle inflammation, muscle disease, which can progress to muscle and muscle, life -threatening - The characteristic manifestations of increased creatine kinase (CK) acute (an increase of more than 10 times on normal (ULN), the appearance of globulin can lead to kidney failure.

Before treatment: CK measurement should be conducted before starting treatment in the following cases:

Renal failure.

During treatment:

Ask the patient to report immediately if muscle pain, cramps, muscle weakness, accompanied by fever or not.

It is necessary to measure CK during treatment with Atorvastatin. Should stop the drug immediately if CK increases more than 5 times ULN or muscle pain symptoms are serious and cause daily discomfort, even if CK ≤ 5 Uln or diagnosed or suspected patients with muscle pilot.

Simultaneously used with other drugs

The

muscle risk still increases as Atorvastatin is simultaneously used with drugs that can increase the concentration of Atorvastatin in plasma such as strong inhibitors CYP3A4 or transport protein (eg Ciclosporin, Telithromycin, Clarithromycin, Delavirdine, Stiripentol, Ketoconazole, Voriconole,, Voriconolate, Voriconol,, Voriconazole Itraconazole, Posaconazole and HIV protease inhibitors include Ritonavir, Lopinavir, Atazanavir, Indinavir, Darunavir, ...).

The risk of muscle disease can also be increased when used simultaneously with gemfibrozil and other fibric acids, BoCeprevir, Erythromycin, Niacin, Ezetimibe, Telaprevir, or use Tipranavir/Ritonavir combination. If possible, consider other medications or other treatments.

The effect of the drug on the ability to drive and operate machinery

Persons who often drive or operate machinery should use drugs?

However, the drug can cause some side effects such as headache, dizziness, blurred vision, tinnitus. If these signs appear should be cautious when driving and operating machinery.

Using drugs for women during pregnancy and lactation

Women during pregnancy should use drugs?

Contraindicated to use Atorvastatin during pregnancy or breastfeeding.

Women who are likely to be pregnant should use effective contraception while treating atorvastatin.

Do not use Atorvastatin if suspected of pregnancy.

Should

Women breastfeeding should take medicine?

No effect.

Drug interaction

CYP3A4 inhibitors

Strong CYP3A4 inhibitors (Cyclosporin, Telithromycin, Clarithromycin, Delavirdine, Stiripentol, Ketoconazole, Voriconazole, Itraconazole, Posaconazole and HIV Protase Inhibitors include Ritonavir, Lopinavir, ActazanAr, ActazanAr, Indinavir, Darunavir, ..) significantly increase Atorvastatin levels. Therefore, avoid using the above drugs with Atorvastatin. If required to be used, should reduce the dose of Atorvastatin and clinical monitoring suitable for patients.

Average CYP3A4 inhibitors (erythromycin, diltiazem, verapamil and fluconazole) may increase the plasma concentration of Atorvastatin. The increased risk of muscle disease has been observed when used in combination with erythromycin and statin. Therefore, it is recommended to use lower doses of maximum atorvastatin and clinical monitoring suitable for patients when used simultaneously with medium inhibitors CYP3A4.

CYP3A4 induction drugs

Simultaneously use Atorvastatin with CYP3A4 induction drugs (such as Efavirenz, Rifampin, which can lead to reduced plasma concentrations of Atorvastatin. Due to the dual interactive mechanism of Rifampin, (CYP3A4 touch and inhibit the liver cells absorb OATP1B1 shipping.

Transport protein inhibitors

Transport protein inhibitors (such as cyclosporine) may increase Atorvastatin levels. If these two drugs cannot be avoided simultaneously, the dose should be reduced and clinically effectively monitored.

derivative of Gemfibrozil/Fibric acid

Fibrats when used alone can cause muscle elimination. When using these medications simultaneously and Atorvastatin increases the risk of muscle pattern. Therefore, avoid simultaneous use of these drugs.

digoxin

When using many doses of digoxin and 10mg atorvastatin, the concentration of digoxin increases slightly. Need to monitor appropriately in patients using digoxin.

contraceptive pills

Be cautious when using Atorvastatin with birth control pills containing norveryron, ethinyl estradiol due to increasing the effects of noruityron, ethinyl estradiol.

Mutual medicine

Due to the absence of studies on the correlation of the drug, not mixing this drug with other drugs.

Storage

Leave a cool place, avoid light, temperature below 30⁰C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.